Legal and Policy Barriers to Telemedicine Prescribing of Controlled Analgesics for Chronic Non-cancer Pain: A Systematic Review

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Background: Telemedicine can reduce travel, geographic, mobility and specialist-access barriers in chronic non-cancer pain (CNCP), but prescribing controlled analgesics remotely is conditioned by overlapping controlled-substance law, patient-location licensure, prescribing standards, monitoring requirements, reimbursement and digital infrastructure. The evidence base is predominantly opioid-focused and has evolved rapidly since the COVID-19 public health emergency. Methods: We conducted a systematic evidence review using PRISMA 2020 principles. On 17 August 2026, structured live searches restricted to PubMed-indexed record pages were performed using prespecified combinations of telemedicine/telehealth, CNCP/chronic pain/long-term opioid therapy, opioid/controlled analgesic, prescribing/monitoring, policy/licensure and implementation terms. Retrieval was supplemented by PMC/Europe PMC verification, citation chaining, related-title/PMID searches, and authoritative legal-policy searches of DEA, HHS, the Federal Register, Reginfo.gov and CDC. Fifty-eight unique empirical records were actually surfaced and screened; 34 underwent report-level assessment and 25 met eligibility criteria. No native subscription-database hit counts were estimated or fabricated. Methodological confidence was appraised using design-appropriate Mixed Methods Appraisal Tool domains, and findings were synthesized narratively because of substantial heterogeneity. Results: The 25 included studies comprised randomized, quasi-experimental, cohort, claims-based, mixed-methods, qualitative and implementation studies, largely from the United States and Canada. Direct-to-patient telemedicine generally supported continuity and access but exposed limitations in video access, physical examination, remote monitoring and patient engagement. Provider-to-provider telementoring commonly improved clinician knowledge and, in several studies, reduced high-dose or otherwise potentially unsafe opioid prescribing. Recurrent barriers were regulatory instability; licensure based on patient location; variation in state prescribing rules; difficulty operationalizing toxicology, physical examination and other safeguards remotely; reimbursement and program sustainability; fragmented EHR, e-prescribing, pharmacy and laboratory workflows; and digital inequity. As of 17 August 2026, qualifying U.S. DEA-registered practitioners may prescribe Schedule II-V controlled substances by telemedicine without a prior in-person evaluation under the temporary federal flexibilities through 31 December 2026, subject to applicable federal and state requirements. DEA’s broader Special Registration rule remained at the final-rule stage rather than being a promulgated permanent replacement. Conclusions: The principal barriers to tele-prescribing controlled analgesics for CNCP arise from fragmented and changing legal authority and from difficulty reproducing selected opioid-safety processes remotely, rather than from evidence that telemedicine is intrinsically unsafe. The most defensible policy model is hybrid and risk-stratified: preserve remote continuity for appropriately selected patients, integrate PDMP and other digital safeguards, maintain local pathways for examination and testing, simplify cross-jurisdiction practice, and replace temporary regulatory extensions with clear durable rules.